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Abstract
Introduction: Several conditions are considered in differential diagnosis of neonatal cholestasis. Of these the
most important is extrahepatic biliary atresia (EHBA), while prompt diagnosis and surgical correction of
obstruction can ameliorate clinical symptoms, provides long term survival for about one fourth of patients and
serves as an important bridge to transplantation for many others. From histopathologic standpoint, features of
EHBA overlaps with other diagnoses and so ancillary tests such as immunohistochemical staining for CD56 is
suggested by some authors as a helpful tool in differential diagnosis.
Hereby we wanted to examine this staining in our center which is a referral children hospital and to prove its
efficacy in our problematic cases.
Materials and Methods: By retrospective review of pathology records during 2000 to 2006 in Markaze Tebbi
Koodakan (children hospital related to Tehran University of Medical Sciences), we selected 17 cases of EHBA as
patients and 12 cases with other diagnoses as controls, both with some degree of bile ductular proliferation in
liver biopsies. EHBA cases were all proved by surgery. Four of control cases also underwent surgery but proved
to have open ducts by intra-operative cholangiography. Long term follow up and other tests ruled out EHBA in
other 8 cases. Hematoxylin-Eosin stains of paraffin blocks were studied again and freshly prepared sections were
immunostained for CD56.
Results: Bile ducts and proliferating bile ductules were strongly positive for CD56 in 6 of 17 cases of EHBA. In
7 out of 17, positivity were seen in more than two thirds of portal tracts. In controls, one case showed strong
positivity and 6 out of twelve showed positivity in more than two thirds of portal tracts. The intensity and
distribution of CD56 staining did not differ significantly between two groups.
Discussion: Despite findings of previous studies, we have shown that CD56 staining can not help as an ancillary
test in differential diagnosis of neonatal cholestasis and perhaps other markers should be tested in this regard.
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Introduction
Extrahepatic biliary atresia is the most common cause of
pathologic infant jaundice and one of the most common
reasons for liver transplantation in children [1]. It is a con-
dition in which there is total or segmental obliteration of
the extrahepatic duct system [2]. Several reports suggest
that it results from prenatal injury and post-inflammatory
fibrous obliteration of extra hepatic biliary tree [2]. Sev-
eral infectious agents such as reovirus 3, rotavirus C,
rubella and cytomegalovirus are suggested as causative
agents [3]. Classically, a 1 to 2 month old child presents
with clay colored stools, jaundice, lack of bile excretion on
cholecintigraphy by hepatobiliary iminodiacetic acid
(HIDA) and a liver biopsy specimen that shows changes
of extrahepatic biliary tract disease with fibrous expansion
of portal tracts and marked bile ductular proliferation [1].
In many cases, the clinical and radiographic findings are
not diagnostic and histologic findings are critical in
patient management decisions. The histologic findings of
EHBA vary depending on when the biopsy is obtained in
the course of the disease. Liver biopsies obtained early in
the course of the disease typically in children younger
than 80 days demonstrate downstream obstructive type
changes with ductular proliferation, variable portal
edema, and lobular cholestasis. Other nonspecific
changes such as focal multinucleated giant hepatocytes
are also seen. Biopsies taken later in the course of the dis-
ease typically show less ductular proliferation and may
show ductopenia [4,5]. The most useful distinguishing
feature is the portal fibrosis and bile duct proliferation in
biliary atresia, although other causes of obstruction and
also some cases of nonobstructive cholestasis may show a
similar pattern such as alpha 1 anti-trypsin deficiency,
cystic fibrosis and progressive familial intrahepatic
cholestasis type III [2,6]. Because of this it is necessary to
prove EHBA by ancillary methods such as immunostain-
ing by CD56 which is reported as helpful aid in differen-
tiating various causes of neonatal cholestasis [1]. CD56 or
N-CAM is an isoform of neural cell adhesion molecule
that is commonly used as a marker of natural killer cells
but is expressed in a variety of normal tissues and also
tumors such as thyroid carcinoma and renal cell carci-
noma [7]. It is not normally expressed in biliary epithe-
lium, but is claimed to be strongly expressed in the setting
of obstructive biliary tract disease [8,9].
The aim of our study was to examine this claim by a case
control study in patients under three months of age who
referred with cholestasis.
Materials and Methods
Pathologic records of patients under 3 months of age were
retrospectively reviewed to identify all cases diagnosed as
EHBA from 2000–2006 in Markaze Tebbi Koodakan
(children hospital related to Tehran University of Medical
Sciences) as well as cases in which biliary atresia was in the
clinical and histological differential diagnosis. We found
191 cases who referred with cholestasis and underwent
liver biopsy, in these we selected 58 cases with final path-
ologic report of "compatible with large bile duct obstruc-
tion" or cases with some degree of bile ductular
proliferation. 29 cases were excluded due to variety of
causes such as incomplete follow up and inadequate spec-
imen. Also patients records were reviewed for clinical and
paraclinical data as presence of acholoic stool, hepat-
osplenomegaly, results of HIDA scan and liver and bile
duct sonography.
All tissues were fixed in 10% neutral buffered formalin.
Five micron sections from the paraffin embedded tissue
(fresh sections were cut for the immunohistochemical
staining as recommended by Torbenson et al [1], because
immunoreactivity of CD56 diminishes in unstained
archival sections kept at room temperature) were stained
with CD56 (clone 1B6, ready to use, Novocastra, Newcas-
tle, UK) using the Novocastra detection system (RE 7150-
K) following heat antigen retrieval by microwave in citrate
(pH: 6). Incubation time of antibody was 30 minutes. All
the slides were seen by one pathologist (F. Mahjoub).
Staining in the interlobular bile ducts and ductules was
evaluated for distribution on a scale of 0 to 3 (as recom-
mended by Torbenson et al) (Table 1). Staining intensity
was also scored on a scale of 0 to 3 (Table 1).
Kupffer cells were served as positive control.
The data were collected and processed by Chi-square and
Fischer's exact tests in SPSS software. A P-value of 0.05 or
less was considered significant.
Table 1: Staining in the interlobular bile ducts and ductules was evaluated for distribution and intensity on a scale of 0 to 3 (as 
recommended by Torbenson et al), depicted in this table.
01 2 3
Distribution No staining Any staining in less than one third of 
portal areas
Staining in one third to less than two 
thirds of portal areas
Staining in more than two thirds of 
portal areas
Intensity No staining Any weak staining Moderate staining Strong stainingDiagnostic Pathology 2008, 3:10 http://www.diagnosticpathology.org/content/3/1/10
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Results
A total of 29 cases were included in the study: seventeen
cases of confirmed biliary atresia and 12 cases of other
conditions consisting of: three cases with final diagnosis
of progressive intrahepatic cholestasis type III (PFIC, III),
three cases with final diagnosis of self-limited cholestatic
hepatitis, two cases of cystic fibrosis (CF), two cases of
inborn errors of metabolic diseases and two cases of neo-
natal giant cell hepatitis. Controls were intentionally
selected to have some degree of bile ductular prolifera-
tion, and in all cases extrahepatic biliary atresia was in the
histologic differential diagnosis. All cases had at least five
portal tracts. Strong positivity for CD56 was detected in 6
of 17 (35.3%) cases of EHBA in both bile ducts and pro-
liferating ductules (score 3) (Table 2). In 7 of 17 cases
(41.2%) more than two thirds of portal tracts showed pos-
itive staining ducts and ductules (score 3) (Fig: 1 &2). Two
cases were negative. Two out of 12 control cases were
completely negative, including one case of neonatal (giant
cell) hepatitis and one case of PFIC type III (Fig 3). One
case of cystic fibrosis showed strong positivity (score 3).
Other control cases showed positivity with intensity rang-
ing from 1 to 2 and distribution score of 1 to 3. Staining
intensity and distribution does not show significant dif-
ference between controls and cases.
Discussion
Extrahepatic biliary atresia is the most common cause of
pathologic infant jaundice and one of the most common
reasons for liver transplantation in children. The diagno-
sis of EHBA can be challenging as the histologic features
can overlap other pediatric cholestatic liver diseases [1]. In
our center we encountered several cases with cholestasis
closer view of picture one (×400) Figure 2
closer view of picture one (×400).
Table 2: Diagnosis of patient in relation to staining intensity and 
distribution for CD56.
No Diagnosis Intensity Distribution
1 Biliary atresia 1 1
2 Biliary atresia 2 2
3 Biliary atresia 3 3
4 Biliary atresia 2 2
5 Biliary atresia 2 2
6 Biliary atresia 3 3
7 Biliary atresia 2 2
8 Biliary atresia 0 0
9 Biliary atresia 2 3
10 Biliary atresia 1 2
11 Biliary atresia 3 3
12 Biliary atresia 3 3
13 Biliary atresia 3 3
14 Biliary atresia 0 0
15 Biliary atresia 3 1
16 Biliary atresia 2 3
17 Biliary atresia 1 1
18 PFIC, TYPE III 1 2
19 PFIC, TYPE III 1 1
20 PFIC, TYPE III 1 2
21 Cholestatic hepatitis of 
unknown etiology
12
22 Cholestatic hepatitis of 
unknown etiology
00
23 Cholestatic hepatitis of 
unknown etiology
23
24 Cystic fibrosis 3 3
25 Cystic fibrosis 1 3
26 Inborn error of metabolism 2 3
27 Inborn error of metabolism 2 3
28 Neonatal (Giant cell) hepatitis 2 3
29 Neonatal (Giant cell) hepatitis 0 0
CD56 immuno-staining: strong positive staining (3) in more  than two third of portal areas (3) Figure 1
CD56 immuno-staining: strong positive staining (3) in more 
than two third of portal areas (3). (×100).Diagnostic Pathology 2008, 3:10 http://www.diagnosticpathology.org/content/3/1/10
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and histologic features resembling EHBA and confirma-
tion by sonography and HIDA scan which were proved to
have patent biliary ducts during surgery. So we decided to
review our cases and also test CD56 staining that is
reported by Torbenson et al to be useful for diagnosis of
EHBA in early ductular proliferative phase. The histopa-
thology of EHBA is essentially that of obstructive extrahe-
patic biliary tract disease. Classically, biopsy specimens
show an extensive ductular proliferation, with elongated
and agulated ductules that occasionally contain bile
plugs. Ductopenia can be seen in biopsies taken later in
the course of the disease, usually in children older than
four months [4,5]. So we decided to study this immunos-
tain only in children less than 3 months of age. The main
differential diagnosis of EHBA are progressive familial int-
rahepatic cholestasis type III, neonatal hepatitis (giant
cell) and cystic fibrosis. Although those with cystic fibrosis
may benefit surgery and washing of inspissated bile plugs,
in the other two conditions surgical operation may be
harmful, hence definite diagnosis especially by histologi-
cal means prior to surgery is critical in these patients.
CD56 is an isoform of N-CAM that serves as an adhesion
molecule for neural cells as well as for natural killer cells.
In addition, it appears that CD56 is upregulated in the bil-
iary tree in situations of extrahepatic biliary tract disease.
Interestingly, other adhesion markers such as ICAM-1 and
VCAM are also upregulated in EHBA, although they were
neither exclusive to nor characteristic of EHBA in Daven-
port study [10]. CD56 also strongly stains bile ducts in the
setting of alcoholic liver disease [11], focal nodular hyper-
plasia [12] and congenital hepatic fibrosis [13]. Also it
commonly stains bile ducts and proliferating ductules in
the setting of TPN (total parenteral nutrition) therapy [8].
In our study a total of 29 cases were included, all under 3
months of age (although in Torbenson's study older chil-
dren were also included), 17 with proved EHBA by surgi-
cal means (14 in Torbenson's study, all proved as ours),
besides we chose cases having needle biopsies rather than
wedge biopsies (which was also included in Torbenson's
study). 12 controls were selected (8 in Torbenson's study),
4 proved to have patent ducts by surgery, and in the
remainder EHBA was ruled out by other means (such as
follow up of patients which revealed a self limited course,
positive sweat test for two times and metabolic tests).
Torbenson reported that bile ducts were positive for CD56
in 13 of 14 cases of EHBA, both bile ducts and proliferat-
ing ductules showed positivity and the staining intensity
was generally strong and in more than two thirds of portal
tracts [1]. However in our study strong positivity was seen
in only 6 of 17 patients with proven EHBA and in one of
12 control cases which was not significant statistically (p
value: 0.18). Distribution of positive staining in EHBA
was in more than two thirds of portal areas in 7 cases from
17 and in 6 from 12 control cases which was not signifi-
cant statistically (p value: 0.6). Differences between two
studies are depicted in Table 3.
We suppose that maybe selection of patients in two stud-
ies (Torbenson's group included older children also),
technical differences and use of both wedge and needle
biopsies by Torbenson has resulted in different findings.
Table 3: Comparison of Torbenson results and our findings. P value of intensity and distribution between two studies were 0.18 and 0.6 
which was not significant statistically.
Torbenson's Article Our Data
CD56 Staining (Number of Cases) CD56 Staining (Number of Cases)
Cases Controls Cases Controls
Neg 1 (small biopsy) 4 Neg 2 2
Pos 13, mostly strong and in more 
than two thirds of portal tracts
3: patchy and weak Pos 15: only 6 strong and only 7 cases 
with positivity in more than two 
thirds of portal tracts.
12: one strong and 6 cases with 
positivity in more than two thirds of 
portal tracts.
Negative CD 56 immuno-staining, only lymphoid cells are  stained and bile ducts and ductuli remain unstained Figure 3
Negative CD 56 immuno-staining, only lymphoid cells are 
stained and bile ducts and ductuli remain unstained.Publish with BioMed Central    and   every 
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Although difference between two groups may become
more prominent on wedge biopsies, we chose only needle
biopsies while we wanted to assess the efficacy of this
method prior to surgical exploration which may be harm-
ful in non EHBA cases.
In summary we conclude that despite Torbenson's results
about utility of CD56 staining in differentiating EHBA
from other causes, better means for this purpose should
be searched for.
Acknowledgements
Hereby we thank Ms Saghi Vaziri and Ms. Zahra Omidi for their devoted 
technical support.
References
1. Torbenson M, Wang J, Abraham S, Maitra A, Boitnott J: Bile ducts
and ductules are positive for CD56 (N-CAM) in most cases
of extrahepatic biliary atresia.  Am J of Sur Pathol 2003,
27(11):1454-1457.
2. Chandra RS: From Liver, Gallbladder and Biliary Tract.  In Pot-
ter's Pathology of the Fetus and Infant Volume 2. 2nd edition. Edited by:
Gilbert Barness E. Missouri: Mosby; 1997:830-857. 
3. Campbell KM: From Biliary atresia.  In Pediatric Gastrointestinal Dis-
ease 4th edition. Edited by: Walker WA. Ontario: BC Decher;
2004:1122-1138. 
4. Landing BH, Wells TR, Ramicone E: Time course of the intrahe-
patic lesion of extrahepatic biliary atresia: A morphometric
study.  Pediatr Pathology 1985, 4:309-319.
5. Raweily EA, Gibson AA, Burt AD: Abnormalities of intrahepatic
bile ducts in extrahepatic biliary atresia.  Histopathology 1990,
17:521-527.
6. Desmet VJ, Rosai J: From Liver, Non-neoplastic Diseases.  In
Ackerman's Surgical Pathology 4th edition. Edited by: Rosai J. Philadel-
phia: Mosby; 2004:949-950. 
7. Dellis RA: From Immunohistology of endocrine tumors.  In
Diagnostic Immunohistochemistry 2nd edition. Edited by: Dabbs D. Phil-
adelphia: Churchil Livingston; 2006:264. 
8. Van Den Heuvel MC, Slooff MJ, Visser L: Expression of anti-OV6
antibody and anti-NCAM antibody along the biliary line of
normal and diseased human livers.  Hepatology 2001,
33:1387-1393.
9. Roskams T, Van den Oord JJ, De Vos R: Neuroendocrine Fea-
tures of Reactive Bile Ductules in Cholestatic Liver Disease.
Am J Pathol 1990, 137:1019-1025.
10. Davenport M, Gonde C, Redkar R: Immunohistochemistry of the
liver and biliary tree in extrahepatic biliary atresia.  J Pediatr
Surg 2001, 36:1017-1025.
11. Chedid A, Mendenhall CL, Moritz TE: The antigenic heterogene-
ity of the bile duct epithelium in alcoholic liver disease: VA
Cooperative Study Group 275.  Arch Pathol Lab Med 1999,
123:411-414.
12. Roskams T, De Vos R, Desmet V: Undifferentiated progenitor
cells in focal nodular hyperplasia of the liver.  Histopathology
1996, 28:291-299.
13. Libbrecht L, Cassiman D, Desmet V, et al.: Expression of neural
cell adhesion molecule in human liver development and in
congenital and acquired liver disease.  Histochem Cell Biol 2001,
116:233-239.